Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 11/20 | 0.49 |
| ▸ | MAOB | P27338 | 8/20 | 0.49 |
| ▸ | MAOA | P21397 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | CALML3 | P27482 | 1/20 | 0.49 |
| ▸ | SDHA | P31040 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10151691 | 0.91 | MAOB (0.61) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL10151687 | 0.90 | MAOB (0.54) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL10151554 | 0.87 | F10 (0.57) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL10152284 | 0.87 | MAOB (0.53) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL10151690 | 0.87 | F10 (0.49) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL10151667 | 0.85 | MAOB (0.53) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL13367939 | 0.85 | F10 (0.55) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL15827718 | 0.85 | F10 (0.50) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL10151680 | 0.85 | MAOB (0.53) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL10151662 | 0.84 | MAOB (0.56) | F10MAOBMAOALMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2009012-B1 | NOVEL COMPOUND HAVING HETEROCYCLIC RING | RES FOUND ITSUU LAB (JP) | 2014-06-25 | — | — | EP | disclosed |
| US-8148362-B2 | Compound having heterocyclic ring | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2012-04-03 | — | — | US | disclosed |
| EP-2181994-A1 | Antimicrobial compounds | Research Foundation Itsuu Laboratory (JP) | 2010-05-05 | — | — | EP | disclosed |
| EP-2181993-A1 | Antimicrobial oxazolidinone derivatives | Research Foundation Itsuu Laboratory (JP) | 2010-05-05 | — | — | EP | disclosed |
| US-20090299059-A1 | Novel Compound Having Heterocyclic Ring | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090299059-A1 | Novel Compound Having Heterocyclic Ring | NR0B2, NR2C2, NR0B1 | F10 3469/4885MAOB 2611/4885MAOA 2965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.